Blog
RSS FeedPosted by Michael Wonder on 09 Apr 2022
PBS listing of Paxlovid (nirmatrelvir and ritonavir)
9 April 2022 - Commencing 1 May 2022, Paxlovid (nirmatrelvir and ritonavir) will be listed on the PBS as a General ...
Posted by Michael Wonder on 09 Apr 2022
PBAC recommendation for nirmatrelvir and ritonavir (Paxlovid) - March 2022
9 April 2022 - The PBAC undertook an expedited consideration of a submission to add the combination product, nirmatrelvir and ritonavir ...
Posted by Michael Wonder on 01 Apr 2022
Public Summary Documents – December 2021 PBAC meeting
1 April 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the December 2021 PBAC ...
Posted by Michael Wonder on 01 Apr 2022
Funding Trikafta for Kiwis with cystic fibrosis - setting the record straight
31 March 2022 - On Monday 28 March, Carmen Shanks presented her Parliamentary Petition to MP Shanan Halbert, urging the ...
Posted by Michael Wonder on 31 Mar 2022
Schedule of Pharmaceutical Benefits - 1 April 2022
1 April 2022 - The April 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Mar 2022
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV
30 March 2022 - The FDA approval of the first dispersible single tablet regimen containing dolutegravir increases age-appropriate treatment options ...
Posted by Michael Wonder on 30 Mar 2022
Cystic fibrosis: early access granted to the Kaftrio/Kalydeco combination
29 March 2022 - The High Authority for Health has authorised early access to a first treatment for children aged 6 ...
Posted by Michael Wonder on 28 Mar 2022
Te Pāti Māori demand accountability from PHARMAC CE for lie about live saving Trikafta drug cost
28 March 2022 - Today Te Pāti Māori stand in solidarity with the cystic fibrosis community of Aotearoa New Zealand ...
Posted by Michael Wonder on 26 Mar 2022
Landmark PBS listing for Australians with cystic fibrosis
27 March 2022 - From April 1 2022, Trikafta (elexacaftor with tezacaftor and ivacaftor and ivacaftor) will be available on ...
Posted by Michael Wonder on 24 Mar 2022
Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis of COVID-19
24 March 2022 - Recommendation based on Phase 3 PROVENT trial showing a significant reduction in the risk of developing ...
Posted by Michael Wonder on 20 Mar 2022
U.S. Food and Drug Administration approves first LAG-3 blocking antibody combination, Opdualag (nivolumab and relatlimab-rmbw), as treatment for patients with unresectable or metastatic melanoma
18 March 2022 - Opdualag is a first in class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and ...
Posted by Michael Wonder on 19 Mar 2022
Heron Therapeutics announces approval of Zynrelef by Health Canada for the management of post-operative pain
17 March 2022 - ZYNRELEF is the first and only extended-release local anaesthetic approved by Health Canada. ...
Posted by Michael Wonder on 15 Mar 2022
FDA approves first generic of Symbicort to treat asthma and COPD
15 March 2022 - Agency supports development of complex generic drug-device combination product to improve competition and access to more affordable ...
Posted by Michael Wonder on 28 Feb 2022
Amylyx Pharmaceuticals announces EMA validation of marketing authorisation application for AMX0035 for the treatment of ALS
25 February 2022 - Amylyx Pharmaceuticals today announced that its marketing authorisation application to the EMA CHMP for AMX0035 (sodium phenylbutyrate ...
Posted by Michael Wonder on 24 Feb 2022
Cystic fibrosis community disappointed with PTAC recommendations
23 February 2022 - New Zealand’s cystic fibrosis community received disappointing news today with a recommendation to PHARMAC that reduces ...